Civilization Ventures

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Aikium is a biotechnology company that specializes in developing novel protein therapeutics for neuro-inflammation and oncology. It combines advancements in synthetic biology and deep learning to create unique, non-antibody scaffold proteins that specifically target and bind to disordered regions of proteins, offering innovative solutions for clients to effectively address disordered proteins.

Catena Biosciences is a biotechnology company focused on advancing protein conjugation technology to develop novel therapeutics for autoimmune disorders, oncology, and vaccine development. The company specializes in the efficient and selective attachment of proteins using natural amino acids, specifically tyrosine and cysteine. This innovative approach allows researchers to create biologic structures more rapidly than traditional methods, enhancing the potential for medical research and treatment options in various disease areas. Catena Biosciences aims to contribute significantly to the field of biomedicine through its cutting-edge technology and applications.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the barriers posed by tumors. By enhancing the effectiveness and durability of immunotherapies, OverT Bio aims to advance the healthcare field's ability to identify and ultimately cure cancer.

Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides, which possess antibody-like binding affinity. Utilizing an automated platform that integrates molecular biology and parallel synthetic chemistry, Insamo aims to rapidly identify preclinical candidates with favorable pharmacological properties. This innovative approach enables the potential replacement of traditional injected or infused biologics with more accessible oral formulations, thereby enhancing patient care. The company's automated design, synthesis, and testing processes allow for unprecedented scalability in the discovery of these therapeutic compounds.

Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to create stabilized, solubilized, and catalytically optimized proteins. Using advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach enables the engineering of biological molecules for applications in agriculture and pharmaceuticals, allowing researchers to enhance the effectiveness and durability of proteins beyond their natural capabilities.

DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.

Range Biotechnologies develops innovative tools focused on personalized health through translational proteomics. The company's technology allows for the precise measurement of multiple proteins across various samples simultaneously. This capability provides healthcare professionals with valuable insights into the fundamental mechanisms of diseases and their progression over time, ultimately advancing human health.

Siren Biotechnology is a biotech company focused on innovating cancer treatment through a unique gene therapy platform. By integrating adeno-associated virus (AAV) gene therapy with cytokine immunotherapy, Siren Biotechnology has developed a novel therapeutic approach. This combination aims to address significant challenges in cancer treatment, including delivery methods, efficacy, and toxicity, ultimately enhancing the elimination of tumor cells and stimulating anti-tumor immunity. Through this redesigned modality, the company seeks to transform the landscape of cancer therapies, offering new hope for patients facing this disease.

Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.

Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Wyndly specializes in personalized allergy treatment and online care, focusing on long-term relief through clinically tested therapies. The company develops allergy treatment options, including a unique drop therapy that targets the underlying causes of allergies, which are often not addressed by traditional antihistamines and nasal sprays. By collaborating with expert providers, Wyndly creates customized treatment plans tailored to the individual needs of clients, offering an affordable and convenient approach to allergy immunotherapy.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Kernal Biologics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on designing and developing mRNA immunotherapies for diseases such as COVID-19 and cancer. Founded in 2016, the company utilizes its mRNA platform to enable specific cells to produce their own therapeutic agents. Kernal's innovative approach has garnered recognition, including awards from notable organizations like Amgen and NASA. The team behind Kernal Biologics has strong ties to prestigious institutions such as MIT and Harvard, along with extensive experience in the biotech sector, which underpins their expertise in the mRNA field.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.

Klivo Health is a healthtech company focused on improving the quality of life for individuals with chronic diseases. The company operates a patient management platform designed to empower users to manage their health more effectively. This platform offers real-time monitoring of medical conditions, facilitates the transmission of blood glucose information, and provides answers to inquiries related to clinical conditions and dietary concerns. By enabling healthcare professionals to access vital patient data, Klivo Health aims to enhance clinical outcomes for those living with chronic conditions, aligning with its mission to add life to years rather than simply extending lifespan. For additional information, interested parties can submit inquiries through the company's website.

Teiko.bio is an immune profiling platform founded in 2020 and based in Salt Lake City, Utah. The company focuses on delivering insights that assist clinicians in making informed decisions regarding patient responses to therapies. Its platform analyzes immune features linked to treatment responses, identifies rational targets for potential combination therapies, and evaluates the abundance and activation levels of various immune cell types. By providing this comprehensive immune profiling, Teiko.bio aims to enhance patient outcomes and facilitate new discoveries in therapeutic pathways.

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.

Catena Biosciences is a biotechnology company focused on advancing protein conjugation technology to develop novel therapeutics for autoimmune disorders, oncology, and vaccine development. The company specializes in the efficient and selective attachment of proteins using natural amino acids, specifically tyrosine and cysteine. This innovative approach allows researchers to create biologic structures more rapidly than traditional methods, enhancing the potential for medical research and treatment options in various disease areas. Catena Biosciences aims to contribute significantly to the field of biomedicine through its cutting-edge technology and applications.

uLab Systems Inc. specializes in developing innovative software technology for digital dental treatment planning aimed at orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create tailored treatment plans based on individual patient needs. Its proprietary architecture and fully automated features enable chairside treatment planning, allowing orthodontists to generate aligner movement plans and fabricate custom aligners in under five minutes. This technology empowers orthodontists to streamline their workflows, reduce laboratory fees, and achieve faster delivery of dental appliances.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Kit is a company focused on providing at-home medical exams and health testing services. It develops comprehensive health testing kits that enable insurers and telehealth companies to offer convenient and safe testing options for their patients from the comfort of their homes. These kits serve as a reliable alternative to traditional doctor and laboratory visits, making preventative health testing accessible across various industries. As a subsidiary of Ro, Kit is committed to enhancing the healthcare experience through innovative solutions.

R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Fluent BioSciences is a life science company focused on single-cell technology, specializing in molecular analysis of cells without the need for complex microfluidic instrumentation. Its proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the rapid self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative technology enhances accessibility to single-cell, molecule, and protein analysis, thereby broadening market access for researchers in biotechnology, pharmaceuticals, and academic institutions.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Gali Health, Inc. is a health technology company based in San Francisco, California, established in 2015. The company focuses on developing a mobile application named Gali, which serves as a personal health assistant designed to support individuals with chronic conditions. By leveraging collective intelligence, Gali enables users to proactively manage their health through crowdsourced personal health data and medically-validated insights. The application employs artificial intelligence to provide highly personalized support, addressing medical, lifestyle, and psychological aspects of living with chronic diseases. Gali Health aims to empower users by ensuring they do not feel isolated or powerless in managing their health, advancing consumer-driven healthcare through innovative technology and personalized health tracking.

DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Wild Earth is a technology startup based in Berkeley, California, founded in 2017. The company specializes in developing sustainable protein pet foods for dogs and cats, focusing on creating healthier options that are also environmentally friendly and humane compared to traditional pet food products. By leveraging scientific advancements, Wild Earth aims to ensure that pets receive all their nutritional needs while promoting a more sustainable approach to pet food production.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Qulab Inc. is a company based in Los Angeles, California, founded in 2017, that focuses on automating the drug design process. By integrating automation and computing technology, Qulab aims to transform research and development practices within the chemical and pharmaceutical sectors. The company utilizes advanced techniques such as computational chemistry, artificial intelligence, and quantum computing to streamline the design of small molecule medications, enhancing efficiency and innovation in drug development.

uLab Systems Inc. specializes in developing innovative software technology for digital dental treatment planning aimed at orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create tailored treatment plans based on individual patient needs. Its proprietary architecture and fully automated features enable chairside treatment planning, allowing orthodontists to generate aligner movement plans and fabricate custom aligners in under five minutes. This technology empowers orthodontists to streamline their workflows, reduce laboratory fees, and achieve faster delivery of dental appliances.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Alveo Technologies, Inc., established in 2014 and based in Alameda, California, specializes in developing infectious disease diagnostic devices. The company's flagship product, be.well, is a comprehensive system that includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. This integrated platform combines nucleic acid detection with molecular biochemistry to identify illnesses such as Flu A/B, COVID-19, and RSV. By leveraging advances in sensing, microfluidics, and bioassays, Alveo aims to empower consumers, healthcare professionals, and treatment providers with early and accurate diagnostic information, facilitating better-informed decisions and improved patient outcomes.

Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

uLab Systems Inc. specializes in developing innovative software technology for digital dental treatment planning aimed at orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create tailored treatment plans based on individual patient needs. Its proprietary architecture and fully automated features enable chairside treatment planning, allowing orthodontists to generate aligner movement plans and fabricate custom aligners in under five minutes. This technology empowers orthodontists to streamline their workflows, reduce laboratory fees, and achieve faster delivery of dental appliances.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. By collecting details about medical history, symptoms, current medications, and allergies, Lemonaid Health employs evidence-based guidelines to provide patients with prescriptions. This approach allows users to access quality healthcare services at a price point lower than typical co-pays, making healthcare more affordable and accessible.

Rocket Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative gene therapies for rare and severe pediatric diseases. The company specializes in lentiviral vector and adeno-associated virus platforms to target genetic disorders. Its lead program focuses on treating Fanconi Anemia, a serious condition that leads to bone marrow failure. In addition to this, Rocket is actively researching therapies for several other bone marrow-derived disorders, including Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis. Furthermore, the company is developing an AAV-based gene therapy for Danon Disease, a multi-organ disorder associated with increased risk of cardiovascular complications. To advance its research, Rocket Pharmaceuticals maintains numerous collaborations and license agreements with prestigious institutions, enhancing its capabilities in gene therapy development. The company is headquartered in New York, New York.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Multerra Bio, Inc. is a San Francisco-based company established in 2015 that specializes in the development of handheld medical devices for diagnostics. These devices utilize a single, consumable cartridge to enable medical professionals to conduct a range of clinical tests efficiently. The company focuses on advancing research programs related to various clinical treatments, aiming to enhance diagnostic capabilities in medical settings.